Literature DB >> 30857448

Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study.

Karolina Babiuch1, Anna Bednarczyk2, Katarzyna Gawlik3, Dorota Pawlica-Gosiewska3, Barbara Kęsek1, Dagmara Darczuk1, Patryk Stępień2, Maria Chomyszyn-Gajewska1, Tomasz Kaczmarzyk1,2.   

Abstract

Objective: The study aimed to evaluate total antioxidant capacity as well as levels of various enzymatic and non-enzymatic antioxidants, and oxidative stress markers in saliva of patients with oral squamous cell carcinoma (OSCC) and oral leukoplakia (OL). Material and methods: Twenty patients with OSCC, 20 patients with OL and 20 healthy subjects were enrolled into this prospective study. Total Antioxidant Capacity (TAC), activity of superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) as well as levels of total glutathione (tGSH), reduced glutathione (GSH), oxidized glutathione (GSSG), GSH/GSSG ratio, uric acid (UA), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and malondialdehyde (MDA) were estimated in saliva using appropriate biochemical methods.
Results: The activity of SOD was significantly higher in OSCC group in comparison with OL and control groups. The levels of GSH were markedly lower in OSCC and OL patients as compared to the control group. Likewise, we found that GSH/GSSG ratio was markedly lower in the OSCC and OL groups. Levels of some biomarkers were influenced by clinical staging of OSCC and OL as well as by sociodemographic factors. Conclusions: The results of this pilot study suggest that salivary activity of SOD is higher in OSCC patients, whereas levels of GSH and GSH/GSSG ratio are lower in saliva of patients with OSCC and OL. Clinical staging of OSCC and OL, as well as some sociodemographic factors may also influence salivary antioxidant status.

Entities:  

Keywords:  Oxidative stress; antioxidants; oral cancer; oral leukoplakia; salivary biomarkers

Mesh:

Substances:

Year:  2019        PMID: 30857448     DOI: 10.1080/00016357.2019.1578409

Source DB:  PubMed          Journal:  Acta Odontol Scand        ISSN: 0001-6357            Impact factor:   2.331


  5 in total

1.  A Case-control Study Comparing and Correlating iNOS Expression among Various Clinicopathological Variants of Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Immunohistochemistry Study.

Authors:  Deepak N Singh; Kumar Chandan Srivastava; Aparna D Potsangbam; Deepti Shrivastava; Doddabasavaiah Basavapur Nandini; Wahengbam T Singh; Koijam S Singh
Journal:  J Pharm Bioallied Sci       Date:  2020-08-28

2.  The Relationship between the Concentration of Salivary Tyrosine and Antioxidants in Patients with Oral Lichen Planus.

Authors:  Dagmara Darczuk; Wirginia Krzyściak; Beata Bystrowska; Barbara Kęsek; Dorota Kościelniak; Maria Chomyszyn-Gajewska; Tomasz Kaczmarzyk
Journal:  Oxid Med Cell Longev       Date:  2019-11-29       Impact factor: 6.543

3.  Malondialdehyde, an Oxidative Stress Marker in Oral Squamous Cell Carcinoma-A Systematic Review and Meta-Analysis.

Authors:  Khadijah Mohideen; Uma Sudhakar; Thayumanavan Balakrishnan; Mazen A Almasri; Manea Musa Al-Ahmari; Hajar Saeed Al Dira; Malath Suhluli; Alok Dubey; Sheetal Mujoo; Zohaib Khurshid; A Thirumal Raj; Shankargouda Patil
Journal:  Curr Issues Mol Biol       Date:  2021-08-28       Impact factor: 2.976

4.  Evaluation of saliva glutathione, glutathione peroxidase, and malondialdehyde levels in head-neck radiotherapy patients

Authors:  Gözde Derindağ; Hayati Murat Akgül; Ahmet Kızıltunç; Halil İbrahim Özkan; Hilal Kızıltunç Özmen; Nilgün Akgül
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

5.  Serum uric acid levels in patients with oral cancer, leukoplakia and submucous fibrosis: a cross-sectional study.

Authors:  Karthik D Yadav; Bharati A Patil; Syed Ahmed Raheel; Abdulwahab Abuderman; Shankargouda Patil; Kamis Gaballah; Omar Kujan
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.